Gotham Asset Management LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 64,220 shares of the company's stock, valued at approximately $2,670,000.
Other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. Compass Planning Associates Inc bought a new stake in Moderna in the 4th quarter valued at $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna in the 4th quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. raised its stake in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. Institutional investors own 75.33% of the company's stock.
Moderna Price Performance
Shares of MRNA stock traded up $1.53 on Monday, hitting $26.39. 16,112,365 shares of the company's stock were exchanged, compared to its average volume of 7,814,209. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The stock has a market cap of $10.21 billion, a P/E ratio of -2.84 and a beta of 1.99. The company has a 50 day moving average of $27.87 and a 200 day moving average of $35.44.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period in the prior year, the company earned ($3.07) EPS. Moderna's revenue for the quarter was down 35.3% on a year-over-year basis. Sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on MRNA shares. Evercore ISI dropped their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. UBS Group dropped their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, William Blair restated a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $53.95.
Read Our Latest Report on MRNA
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
